EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE Drug Patent Profile

When do Emtricitabine And Tenofovir Disoproxil Fumarate patents expire, and when can generic versions of Emtricitabine And Tenofovir Disoproxil Fumarate launch?

Emtricitabine And Tenofovir Disoproxil Fumarate is a drug marketed by Hetero Labs Ltd Iii and is included in one NDA.

The generic ingredient in EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE is emtricitabine; tenofovir disoproxil fumarate. There are eighteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Emtricitabine And Tenofovir Disoproxil Fumarate

A generic version of EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8^th, 2017.

Summary for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	5
Clinical Trials:	187
DailyMed Link:	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE at DailyMed

Recent Clinical Trials for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
HIV Prevention Trials Network	PHASE2
Abdelrahman Mahmoud	PHASE2
Instituto Mexicano del Seguro Social	PHASE4

See all EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE clinical trials

Pharmacology for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	201806-001	Oct 7, 2021	AB	RX	No	No

Market Dynamics and Financial Trajectory for Emtricitabine and Tenofovir Disoproxil Fumarate

Last updated: February 15, 2026

Summary

Emtricitabine combined with Tenofovir Disoproxil Fumarate (TDF) is a core component of antiretroviral therapy (ART) for HIV treatment and pre-exposure prophylaxis (PrEP). The drugs' market landscape is shaped by patent expirations, entry of generic versions, evolving treatment guidelines, and increasing demand driven by global HIV/AIDS prevalence and preventive health initiatives. Projected revenues are expected to grow amid expanding access, yet face competitive pressures from newer formulations and generics.

Market Size and Growth Drivers

Globally, the HIV drug market is valued at approximately $20 billion in 2023, with emtricitabine/TDF constituting a significant subset. Key factors influencing market growth include:

• High HIV prevalence, estimated at 38 million people worldwide, with sub-Saharan Africa accounting for over 60%.[1]
• Adoption of ART as standard care, with 28 million people on treatment globally.[2]
• Expansion of PrEP programs, especially in North America, Europe, and select Asian countries.
• Public health initiatives subsidizing access, particularly through the Global Fund and PEPFAR.

The combination's market share is diminishing gradually due to:

• Patent expiration of Truvada (Gilead’s branded emtricitabine/TDF) in multiple jurisdictions by 2020–2024.
• The entry of low-cost generic formulations increasing affordability.
• Introduction of newer drugs with improved safety profiles, such as tenofovir alafenamide (TAF)-based products.

Patent and Generic Entry Timeline

Year	Key Patent Milestones	Impact
2016	Gilead's Truvada patent expiration begins in some regions	Entry of generics reduces prices
2020-2024	Global patent expirations for Truvada	Surge in generic availability
2021	Gilead introduces TAF-based alternatives; TDF sales decline	Shift toward TAF-based regimens

Financial Projections

Gilead’s emtricitabine/TDF franchise historically generated over $3 billion annually at peak. Post patent expiry, revenue declines are projected unless supplemented with new formulations. Generics in key markets (e.g., India, China) have driven prices down by approximately 60%–70%.[3]

Market analysts forecast:

• A compound annual growth rate (CAGR) of approximately 3-5% for the overall HIV-related ART market from 2023 to 2030.
• The branded emtricitabine/TDF segment to decline by over 10% annually post-2023 unless replaced or supplemented by TAF formulations.

Competitive Environment

• Gilead’s TAF-based therapies, such as Descovy, gain market share at the expense of TDF formulations due to better renal and bone safety profiles.
• Several generic manufacturers, including Mylan and Cipla, offer affordable emtricitabine/TDF products.
• The development pipeline includes long-acting injectables, which could further influence traditional oral therapy markets.

Pricing Trends

• Brand-name Truvada prices in high-income countries remain around $1,800–$2,000 per month.
• Generics cost $200–$400 per month in low- and middle-income countries.
• Price erosion accelerates in markets with robust generic competition.

Regulatory and Policy Factors

• WHO recommends TAF-based regimens over TDF where available, influencing formulary preferences.
• Patent rights and exclusivity periods vary: in the U.S., key patents expired in 2020; in the EU, expires continue into 2025.
• Governments and NGOs transition towards generic and TAF-based regimens, affecting revenue streams.

Key Takeaways

• The market for emtricitabine and TDF is transitioning from branded dominance to a heavily partialized landscape dominated by generics and alternative formulations.
• Revenue declines are offset globally by increased treatment coverage and PrEP uptake, yet the branded market faces ongoing erosion.
• The advent of TAF-based therapies offers a pathway for branded products to sustain relevance but may require innovation and pricing strategies.
• Pricing pressures and patent expirations are critical factors shaping future financial trajectories.
• Investment opportunities exist in next-generation formulations and in markets expanding access to HIV treatment and prevention.

FAQs

1. What factors influence the decline of branded emtricitabine/TDF revenues?
   Patent expirations, generic competition, and the shift toward TAF formulations reduce brand sales.

2. How does the introduction of TAF-based therapies impact the market?
   TAF therapies have better safety profiles and are replacing TDF-based drugs, shifting revenue both toward newer products and diminishing TDF sales.

3. Which regions are most affected by generic entry?
   India, China, and other low- and middle-income countries see the most significant price reductions due to local generic manufacturing.

4. What role do regulatory decisions play?
   Regulatory approvals for generics and new formulations determine market entry timelines and influence pricing and reimbursement policies.

5. Will the demand for emtricitabine and TDF persist long-term?
   Yes, especially for PrEP and in regions with limited access to newer formulations, although market share will decline relative to TAF-based therapies.

Sources

[1] UNAIDS, 2023 Global HIV/AIDS Statistics
[2] WHO, HIV Treatment Coverage Update, 2023
[3] IQVIA, Global Generic Drug Market Data, 2023